+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The role of retinoid x receptor mrna expression in barretts esophagus and barretts associated adenocarcinoma of the esophagus



The role of retinoid x receptor mrna expression in barretts esophagus and barretts associated adenocarcinoma of the esophagus



Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 501



Objective The Barrett`s multistage process is characterized histopathologically by progression from Barrett`s intestinal metaplasia to Barrett`s esophagus with dysplasia and ultimately adenocarcinoma. Understanding of the molecular alterations in this multistage process may contribute to improved diagnosis and treatment. Retinoid X Receptors (RXR) play an important role in regulating the morphogenesis, development, growth, and differentiation of cells. Alterations in RXR expression have been observed in a variety of solid tumors, however the role in Barrett`s esophagus disease has yet to be determined. Aim of this study was to assess the prevalence and timing of RXR mRNA expression in Barrett`s metaplasia-dysplasia-adenocarcinoma sequence and to determine its role for the development and progression of this disease. Methods We analyzed the mRNA expression of all 3 RXR subtypes (RXR-alpha, RXR-beta, RXR-gamma) by using a quantitative real-time RT-PCR method (Taqman) in 108 specimens from 19 patients with Barrett`s esophagus without carcinoma (BE-group), 20 patients with Barrett`s associated adenocarcinoma (EA-group), and a control group of 10 patients without evidence of gastro-esophageal reflux disease (CG). Results RXR-alpha mRNA expression was significantly decreased (p<0.001; Kruskal-Wallis test), and RXR-gamma (p<0.001) was significantly increased at higher stages in Barrett`s esophgus disease. RXR-beta expression was highest in Barrett`s tissues and significantly increased compared to normal squamous tissues (p=0.01, Wilcoxon test) and adenocarinoma tissues (p=0.018, Mann-Whitney test). RXR-alpha and RXR-beta mRNA expression were significantly associated in normal squamous esophagus tissues (r2=0.49; p<0.001; Spearman test), Barrett`s tissues (r2=0.63; p<0.001), and adenocarcinoma tissues (r2=0.68; p=0.001). There were significant differences in RXR-alpha (p=0.011) and RXR-beta (p=0.005) mRNA expression in histopathologically normal squamous esophagus tissues in patients with cancer and the normal control group(CG). Conclusions These findings suggest that alterations in the mRNA expression of all 3 RXR subtypes are frequent events in the development and progression of Barrett`s esophagus and associated adenocarcinoma, that quantitation of RXR mRNA expression may be useful biomarkers for this disease, and that a widespread field-effect is present in the normal esophagus of patients with esophageal adenocarcinoma.

(PDF emailed within 0-6 h: $19.90)

Accession: 035930377

Download citation: RISBibTeXText

DOI: 10.1016/s0016-5085(03)83987-2


Related references

Quantitative mRNA expression analysis of multiple genes distinguish between Barretts-esophagus and Barretts-associated adenocarcinoma of the esophagus. Proceedings of the American Association for Cancer Research Annual Meeting 43: 464-465, 2002

Recurrence of columnar lined esophagus segments after surgery for Barretts associated adenocarcinoma The natural history of Barretts esophagus. Gastroenterology 118(4 Suppl 2 Part 1): A222, 2000

Expression of trefoil factors in Barretts esophagus, dysplasia and adenocarcinoma arising in Barretts. Laboratory Investigation 82(1): 124A-125A, 2002

CD44st and CD44v6 splice variant expression in Barretts esophagus and Barretts adenocarcinoma. Gastroenterology 112(4 SUPPL ): A595, 1997

Correlation between the gene expression profiles of adenocarcinoma of esophagus and Barretts esophagus. Chinese-German Journal of Clinical Oncology 9(1): 26-30, 2010

Barretts metaplasia and Barretts adenocarcinoma of the esophagus MIB 1, BCL-2, type IV collagen, type IV collagenase and cathepsin D expression. Modern Pathology 8(1): 59A, 1995

P53 protein overexpression in Barretts adenocarcinoma and Barretts esophagus in paraffin embedded tissue. Gastroenterology 104(4 SUPPL ): A1045, 1993

Is the length of Barretts mucosa related to the prevalence of complications and adenocarcinoma in Barretts esophagus?. Gastroenterology 104(4 SUPPL ): A393, 1993

Glutathione S-transferase P1 mRNA expression is down-regulated in patients with Barretts esophagus and esophageal adenocarcinoma. Gastroenterology 120(5 Suppl. 1): A 344, 2001

Gastric Helicobacter pylori infection is associated with Barretts adenocarcinoma but not Barretts esophagus. Gastroenterology 116(4 PART 2): A319, 1999

Time-dependent expression of inducible nitric oxide synthase in a rat model for Barretts esophagus and adenocarcinoma of the esophagus. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 353, 1997

Study of p53 gene mutations and serum anti-p53 antibodies in Barretts esophagus and short segment Barretts esophagus. Gastroenterology 118(4 Suppl 2 Part 2): AGA A1319, 2000

Detection of numerical chromosomal aberrations in Barretts adenocarcinoma and Barretts esophagus by non-isotopic in situ hybridisation to tumour sections. Gastroenterology 104(4 SUPPL ): A1045, 1993

Does more Barretts really mean mode cancer? Comparison of incidence rates of adenocarcinoma in prospectively followed patient cohorts with short and long segments of Barretts esophagus. Gastroenterology 114(4 PART 2): A674, April 15, 1998

A multigene expression panel for the molecular diagnosis of Barretts esophagus and Barretts cancers. Gastroenterology 122(4 Suppl 1): A 16-A 17, 2002